

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: Anders Lehmann et al.
Serial No.	: 10/517,869
Filing or 371(c) Date	: October 12, 2005
For	: USE OF MgLur5 ANTAGONISTS FOR THE TREATMENT OF GERD
Examiner	: Spivack, Phyllis G.
Group Art Unit	: 1614

CERTIFICATE OF EFS-WEB TRANSMISSION	
I hereby certify that this paper is being transmitted via the Electronic Filing System to the U.S. Patent and Trademark Office on the date indicated below.	
<u>/John M. Genova/</u>	<u>32,224</u>
Signature	Reg. No.
<u>John M. Genova</u>	<u>17 August 2010</u>
Signer's Name	Date

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

A Notice of Allowance was mailed 19 May 2010 in connection with the referenced application. The required publication and issue fees have not been paid.

In accordance with 37 C.F.R. §1.313(a), Applicants request the Office to withdraw the application from issue and consider the documents listed on the accompanying Form PTO/SB/08a. Concurrent with this Information Disclosure Statement ("IDS"), Applicants are filing a Request for Continued Examination pursuant to 37 C.F.R. §1.114(a).

By an IDS filed 4 May 2009, Applicants made of record two post-grant oppositions, and documents cited in support thereof, filed against the granted European patent EP 1 513 525 B1

belonging to the same patent family as the referenced U.S. application. The opposition is pending and a hearing before the Opposition Division of the European Patent Office (“EPO”) is scheduled for 28 September 2010.

By this IDS, Applicants wish to disclose the following opposition-related documents that were filed with the EPO after Applicants’ IDS of 4 May 2009:

- 1) the patentee AstraZeneca’s response, dated 25 June 2009, to each opposition;
- 2) the EPO’s preliminary and non-binding opinion dated 19 October 2009;
- 3) a supplemental submission, dated 28 July 2010, by the opponent Novartis AG;
and
- 4) Trilateral Project B3b: Mutual understanding in search and examination: Report on comparative study on biotechnology patent practices: Theme – comparative study on “reach-through claims”, EPO, JPO, USPTO, November 5-9, 2001.

Document 4, Trilateral Project B3b, is an attachment to document 3), opponent Novartis’s supplemental submission.

If any fee is required, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: 17 August 2010

Respectfully submitted,

/John M. Genova/
John M. Genova
Reg. No. 32,224

Customer No. 007470
Direct Dial: (212) 819-8832